Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND3 | P30281 | 2/20 | 0.51 |
| ▸ | CCNK | O75909 | 1/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | CDK9 | P50750 | 1/20 | 0.51 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | JAK3 | P52333 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
| ▸ | CCND1 | P24385 | 1/20 | 0.45 |
| ▸ | CCND2 | P30279 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 9/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14927017 | 0.89 | WNT3A (0.46) | CCND3CCNKCCNA2CDK2CDK9 | |
| SCHEMBL15550868 | 0.86 | SYK (0.48) | SYKCD63 | |
| SCHEMBL15550428 | 0.86 | JAK3 (0.51) | JAK2JAK3NAMPTPTK2GPR119 | |
| SCHEMBL30806184 | 0.84 | SYK (0.43) | MAPTKMT2ASMN1; SMN2JAK2AURKA | |
| SCHEMBL2217712 | 0.83 | SYK (0.64) | JAK2JAK3AURKASYKCD63 | |
| SCHEMBL30806176 | 0.83 | SYK (0.54) | CCND3CCNKCCNA2CDK2CDK9 | |
| SCHEMBL30806172 | 0.82 | AURKA (0.45) | MEN1KMT2AJAK2AURKASYK | |
| SCHEMBL10256167 | 0.81 | CCND3 (0.49) | CCND3CCNKCCNA2CDK2CDK9 | |
| SCHEMBL30783301 | 0.81 | CCND3 (0.51) | CCND3CCNKCCNA2CDK2CDK9 | |
| SCHEMBL21471583 | 0.80 | AURKA (0.42) | CCND3MAPTJAK2JAK3AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110177011-A1 | CERTAIN IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES AND METHOD OF INHIBITION OF BRUTON'S TYROSINE KINASE BY SUCH COMPOUNDS | CURRIE KEVIN S | 2011-07-21 | — | — | US | disclosed |
| US-20110177011-A1 | CERTAIN IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES AND METHOD OF INHIBITION OF BRUTON'S TYROSINE KINASE BY SUCH COMPOUNDS | CURRIE KEVIN S | 2011-07-21 | — | — | US | disclosed |
| US-20110177011-A1 | CERTAIN IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES AND METHOD OF INHIBITION OF BRUTON'S TYROSINE KINASE BY SUCH COMPOUNDS | CURRIE KEVIN S | 2011-07-21 | — | — | US | disclosed |
| US-7405295-B2 | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds | CGI PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405295-B2 | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds | CGI PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405295-B2 | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds | CGI PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20060183746-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds | CGI PHARMACEUTICALS, INC. | 2006-08-17 | — | — | US | disclosed |
| US-20050090499-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton's tyrosine kinase by such compounds | GILEAD CONNECTICUT, INC. | 2005-04-28 | — | — | US | disclosed |
| WO-2005014599-A1 | IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES AND METHOD OF INHIBITION OF BRUTON’S TYROSINE KINASE BY SUCH COMPOUNDS | CELLULAR GENOMICS, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090499-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton's tyrosine kinase by such compounds | BTK, SYK, JAK1 | CCND3 703/4885CCNK 362/4885CCNA2 481/4885 |
| US-20110177011-A1 | CERTAIN IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES AND METHOD OF INHIBITION OF BRUTON'S TYROSINE KINASE BY SUCH COMPOUNDS | BTK, SYK, JAK1 | CCND3 703/4885CCNK 362/4885CCNA2 481/4885 |
| US-20060183746-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds | BTK, SYK, LCK | CCND3 839/4885CCNK 205/4885CCNA2 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.